Drug Profile


Alternative Names: ARA 290

Latest Information Update: 29 Nov 2016

Price : $50

At a glance

  • Originator Araim Pharmaceuticals
  • Developer Araim Pharmaceuticals; Karolinska Institute; Queens University Belfast
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Peptides
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis; Transplant rejection; Neuropathic pain
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Neuropathic pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders; Diabetic macular oedema; Diabetic neuropathies; Ischaemia; Neuropathic pain; Rheumatoid arthritis; Type 2 diabetes mellitus
  • Preclinical Radiation injuries; Retinal disorders; Transplant rejection

Most Recent Events

  • 28 Nov 2016 Cibinetide receives Orphan Drug status for Transplant rejection (Prevention) in European Union
  • 25 Jul 2016 Cibinetide receives Orphan Drug status for Transplant rejection (Prevention) in USA
  • 05 Jul 2016 Cibinetide receives Orphan Drug status for Sarcoidosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top